Determination of new biomarkers in the plasma proteome;Påvisning av nye biomarkører i plasma-proteomet

Norsk Epidemiologi

Volumn 16, Issue 1, 2006, Pages 35-40

  Berg, Jens P ^a,b   Henninge, John ^a   Lund, Terje ^a  

^a AKER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; BIOLOGICAL MARKER; C PEPTIDE; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C9; COMPLEMENT FACTOR H; CREATINE KINASE; FERRITIN; FIBRINOGEN; GAMMA INTERFERON; HAPTOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INSULIN; INTERLEUKIN 8; LIPOPROTEIN A; MYOGLOBIN; PEPTIDE; PLASMA PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEOME; RETINOL BINDING PROTEIN; TRANSFERRIN; TROPONIN; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA;

BLOOD ANALYSIS; CANCER GROWTH; CANCER RISK; DISEASE MARKER; GENETIC ANALYSIS; GENETIC DISORDER; HIGH RISK POPULATION; HUMAN; IMMUNOASSAY; IN VITRO STUDY; LABORATORY TEST; MASS SPECTROMETRY; PROPHYLAXIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW;

EID: 33645035414     PISSN: 08032491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Forsman RW. The value of the laboratory professional in the continuum of care. Clin Leadersh Manag Rev 2002; 16 (6): 370-3.
2. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002; 1 (11): 845-67.
3. Thadikkaran L, Siegenthaler MA, Crettaz D, et al. Recent advances in blood-related proteomics. Proteomics 2005; 5 (12): 3019-34.
4. A J, Trygg J, Gullberg J, et al. Extraction and GC/MS analysis of the human blood plasma metabolome. Anal Chem 2005; 77 (24): 8086-94.
5. Ping P, Vondriska TM, Creighton CJ, et al. A functional annotation of subproteomes in human plasma. Proteomics 2005; 5 (13): 3506-19.
6. Anderson NL, Polanski M, Pieper R, et al. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 2004; 3 (4): 311-26.
7. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36 (3): 959-69.
8. Anderson NG. Computer interfaced fast analyzers. Science 1969; 166 (903): 317-24.
9. Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement Thyroid 1999; 9 (5): 435-41.
10. Haab BB. Antibody arrays in cancer research. Mol Cell Proteomics 2005; 4 (4): 377-83.
11. Schweitzer B, Roberts S, Grimwade B, et al. Multiplexed protein profiling on microarrays by rolling-circle amplification. Nat Biotechnol 2002; 20 (4): 359-65.
12. Klose J. Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues. A novel approach to testing for induced point mutations in mammals. Humangenetik 1975; 26 (3): 231-43.
13. Jellum E, Thorsrud AK. Clinical applications of two-dimensional electrophoresis. Clin Chem 1982; 28 (4 Pt 2): 876-83.
14. Wang YY, Cheng P, Chan DW. A simple affinity spin tube filter method for removing high-abundant common proteins or enriching low-abundant biomarkers for serum proteomic analysis. Proteomics 2003; 3 (3): 243-8.
15. Bjorhall K, Miliotis T, Davidsson P. Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples. Proteomics 2005; 5 (1): 307-17.
16. Guerrera IC, Kleiner O. Application of mass spectrometry in proteomics. Biosci Rep 2005; 25 (1-2): 71-93.
17. rd. Mass spectral analysis in proteomics. Annu Rev Biophys Biomol Struct 2004; 33: 297-316.
18. Pusch W, Kostrzewa M. Application of MALDI-TOF mass spectrometry in screening and diagnostic research. Curr Pharm Des 2005; 11 (20): 2577-91.
19. Seibert V, Wiesner A, Buschmann T, Meuer J. Surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI TOP-MS) and ProteinChip technology in proteomics research. Pathol Res Pract 2004; 200 (2): 83-94.
20. Listgarten J, Emili A. Statistical and computational methods for comparative proteomic profiling using liquid chromatography-tandem mass spectrometry. Mol Cell Proteomics 2005; 4 (4): 419-34.
21. rd. Shotgun proteomics and biomarker discovery. Dis Markers 2002; 18 (2): 99-105.
22. rd. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001; 19 (3): 242-7.
23. Kelleher NL. Top-down proteomics. Anal Chem 2004; 76 (11): 197A-203A.
24. Anderson NL, Hunter CL. Quantitative mass spectrometric MRM assays for major plasma proteins. Mol Cell Proteomics, In press.
25. Liotta LA, Petricoin EF. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 2006; 116 (1): 26-30.
26. Hwang IK, Park SM, Kim SY, Lee ST. A proteomic approach to identify substrates of matrix metalloproteinase-14 in human plasma. Biochim Biophys Acta 2004; 1702 (1): 79-87.
27. Villanueva J, Shaffer DR, Philip J, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006; 116 (1): 271-84.
28. Veenstra TD, Conrads TP, Hood BL, et al. Biomarkers: mining the biofluid proteome. Mol Cell Proteomics 2005; 4 (4): 409-18.
29. Omenn GS, States DJ, Adamski M, et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005; 5 (13): 3226-45.